工具和标准用于选择晚期帕金森病患者接受器械辅助治疗：叙述性综述。
Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.
机构信息
Department of Neurology, University of Groningen, University Medical Center Groningen, 9713 GZ, Groningen, The Netherlands.
Department of Neurology, Movement Disorder Clinic, Bispebjerg Hospital, Copenhagen, Denmark.
出版信息
J Neural Transm (Vienna). 2023 Nov;130(11):1359-1377. doi: 10.1007/s00702-023-02656-z. Epub 2023 Jul 27.
Abstract
This article provides an overview of the various screening and selection tools which have been developed over the past 25 years to identify patients with Parkinson's disease (PD) possibly eligible for device-aided therapies (DATs). For the available screening tools, we describe the target therapies (subtypes of DAT), development methods, validation data, and their use in clinical practice. In addition, the historical background and potential utility of these screening tools are discussed. The challenges in developing and validating these tools are also addressed, taking into account the differences in population, the local health care organization, and resource availability.
摘要
本文概述了过去 25 年来为识别可能适合接受设备辅助治疗（DAT）的帕金森病（PD）患者而开发的各种筛选和选择工具。对于现有的筛选工具，我们描述了其目标治疗方法（DAT 亚型）、开发方法、验证数据及其在临床实践中的应用。此外，还讨论了这些筛选工具的历史背景和潜在用途。在考虑到人群、当地医疗保健组织和资源可用性的差异的情况下，还讨论了开发和验证这些工具所面临的挑战。
相似文献
1
Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.工具和标准用于选择晚期帕金森病患者接受器械辅助治疗：叙述性综述。
J Neural Transm (Vienna). 2023 Nov;130(11):1359-1377. doi: 10.1007/s00702-023-02656-z. Epub 2023 Jul 27.
2
Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.长期应用器械辅助治疗并单药治疗：一项以色列晚期帕金森病患者队列的回顾性分析。
Adv Ther. 2022 May;39(5):2009-2024. doi: 10.1007/s12325-022-02072-x. Epub 2022 Mar 5.
3
[Selection of the optimal device-aided therapy in Parkinson's disease].[帕金森病最佳器械辅助治疗的选择]
Ideggyogy Sz. 2019 Jan 30;72(1-2):5-11. doi: 10.18071/isz.72.0005.
4
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.美国在门诊开始使用左旋多巴-卡比多巴肠凝胶治疗晚期帕金森病的现行做法。
Adv Ther. 2019 Sep;36(9):2233-2246. doi: 10.1007/s12325-019-01014-4. Epub 2019 Jul 5.
5
Infusion Therapies in the Treatment of Parkinson's Disease.输注治疗在帕金森病中的应用。
J Parkinsons Dis. 2023;13(5):641-657. doi: 10.3233/JPD-225112.
6
Device-aided therapies for advanced Parkinson disease: insights from an international survey.辅助设备治疗晚期帕金森病：国际调查的新见解。
Neurol Sci. 2021 Jul;42(7):2961-2964. doi: 10.1007/s10072-021-05106-4. Epub 2021 Feb 6.
7
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.左旋多巴-卡比多巴肠凝胶（LCIG）用于晚期帕金森病患者的常规护理：一项关于有效性、耐受性和医疗成本的开放标签前瞻性观察性研究。
Parkinsonism Relat Disord. 2016 Aug;29:17-23. doi: 10.1016/j.parkreldis.2016.06.002. Epub 2016 Jun 4.
8
Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications".给编辑的信，“MANAGE-PD 工具的验证和临床价值：一种用于识别口服药物治疗控制不佳的帕金森病患者的临床报告工具”。
Parkinsonism Relat Disord. 2022 Apr;97:99-100. doi: 10.1016/j.parkreldis.2022.03.014. Epub 2022 Mar 28.
9
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.在运动障碍专家中就识别和管理晚期帕金森病的临床指标达成共识：一项多国德尔菲小组方法。
Curr Med Res Opin. 2018 Dec;34(12):2063-2073. doi: 10.1080/03007995.2018.1502165. Epub 2018 Aug 20.
10
The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.设备辅助疗法对帕金森病肠道微生物组的影响。
J Neurol. 2022 Feb;269(2):780-795. doi: 10.1007/s00415-021-10657-9. Epub 2021 Jun 15.
引用本文的文献
1
Motor and non-motor fluctuations in Parkinson's disease: the knowns and unknowns of current therapeutic approaches.帕金森病的运动和非运动波动：当前治疗方法的已知与未知
J Neural Transm (Vienna). 2025 Jul 28. doi: 10.1007/s00702-025-02990-4.
2
Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study.帕金森病（PD）的器械辅助治疗（DATs）。DATs-PD GETM西班牙注册协议研究。
PLoS One. 2025 Mar 31;20(3):e0316052. doi: 10.1371/journal.pone.0316052. eCollection 2025.
3
Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential.评估帕金森病患者阿扑吗啡治疗的适用性：远程监测的潜力
Mov Disord Clin Pract. 2025 Feb 11. doi: 10.1002/mdc3.14345.
4
The role of intraoperative monitoring in target selection in deep brain stimulation: A single centre study.术中监测在脑深部电刺激靶点选择中的作用：一项单中心研究。
Clin Park Relat Disord. 2025 Jan 6;12:100299. doi: 10.1016/j.prdoa.2025.100299. eCollection 2025.
5
Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease.使用MNCD分类法监测晚期帕金森病的临床分期及对左旋多巴-恩他卡朋-卡比多巴肠凝胶输注的反应
Brain Sci. 2024 Dec 12;14(12):1244. doi: 10.3390/brainsci14121244.
6
Utilization of MANAGE-PD Tool in a Real-World Setting in Germany: A Cross-Sectional Study.MANAGE-PD工具在德国真实环境中的应用：一项横断面研究。
Brain Sci. 2024 Jun 24;14(7):630. doi: 10.3390/brainsci14070630.
7
Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies.把握大局：及时转介至器械辅助治疗的筛查工具的影响分析。
J Neural Transm (Vienna). 2024 Nov;131(11):1295-1305. doi: 10.1007/s00702-024-02783-1. Epub 2024 Jul 15.
8
What was first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing evidence and experience.在帕金森病中选择器械辅助治疗，首先要考虑什么，接下来又该考虑什么？权衡证据与经验。
J Neural Transm (Vienna). 2024 Nov;131(11):1307-1320. doi: 10.1007/s00702-024-02782-2. Epub 2024 May 15.
9
Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience.左旋多巴-恩他卡朋-卡比多巴肠凝胶治疗晚期帕金森病：单中心真实世界经验
Pharmaceutics. 2024 Mar 25;16(4):453. doi: 10.3390/pharmaceutics16040453.
10
Patient Referral for Device-Aided Therapies in Parkinson's Disease is Suboptimal; A Dutch Survey.帕金森病患者接受器械辅助治疗的转诊情况不理想；一项荷兰调查。
Mov Disord Clin Pract. 2023 Nov 11;10(12):1821-1823. doi: 10.1002/mdc3.13913. eCollection 2023 Dec.
本文引用的文献
1
Timely referral for device-aided therapy in Parkinson's disease. Development of a screening tool.帕金森病中设备辅助治疗的及时转诊。一种筛查工具的开发。
Parkinsonism Relat Disord. 2023 Apr;109:105359. doi: 10.1016/j.parkreldis.2023.105359. Epub 2023 Mar 8.
2
Off-time Treatment Options for Parkinson's Disease.帕金森病的非按时治疗选择
Neurol Ther. 2023 Apr;12(2):391-424. doi: 10.1007/s40120-022-00435-8. Epub 2023 Jan 12.
3
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.辅助设备治疗对晚期帕金森病患者生活质量和无关时间的疗效比较：系统评价和贝叶斯网络荟萃分析。
CNS Drugs. 2022 Dec;36(12):1269-1283. doi: 10.1007/s40263-022-00963-9. Epub 2022 Nov 21.
4
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性：一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
5
Device-Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta-Analysis.设备辅助和神经调节疗法治疗帕金森病：网络荟萃分析。
Mov Disord. 2022 Sep;37(9):1785-1797. doi: 10.1002/mds.29160. Epub 2022 Jul 22.
6
European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.欧洲神经病学学会/运动障碍学会-欧洲分部关于帕金森病治疗的指南：I. 侵袭性治疗。
Mov Disord. 2022 Jul;37(7):1360-1374. doi: 10.1002/mds.29066. Epub 2022 Jul 6.
7
Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance.左旋多巴-恩他卡朋-卡比多巴肠凝胶输注治疗晚期帕金森病：真实世界经验与实践指南
Ther Adv Neurol Disord. 2022 Jun 26;15:17562864221108018. doi: 10.1177/17562864221108018. eCollection 2022.
8
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease.静脉内（DIZ101）、皮下（DIZ102）和肠内（LCIG）输注左旋多巴治疗晚期帕金森病的药代动力学。
Neurology. 2022 Sep 5;99(10):e965-e976. doi: 10.1212/WNL.0000000000200804.
9
A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.单基因帕金森病和 GBA 变异携带者对设备辅助治疗的反应综述：需要制定指南和开展比较研究。
J Parkinsons Dis. 2022;12(6):1703-1725. doi: 10.3233/JPD-212986.
10
Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.跨国比较帕金森病晚期症状和管理：来自 OBSERVE-PD 观察性研究的分析。
Acta Neurol Scand. 2022 Aug;146(2):167-176. doi: 10.1111/ane.13648. Epub 2022 May 24.
Zotero 插件